相关实验视频

Updated: Jul 5, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

在初级胆道胆炎和肠道微生物群的治疗成功:安全的高速公路?

Ludovico Abenavoli¹, Giuseppe Gm Scarlata², Emidio Scarpellini³

¹Department of Health Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy - l.abenavoli@unicz.it.

Minerva gastroenterology

|January 19, 2024

概括

本综述检查了原发性胆道胆炎 (PBC) 患者的肠道微生物群变化,在 Ursodeoxycholic 酸 (UDCA) 治疗前后. 了解这些转变可能会揭示这种自身免疫性肝病治疗反应的新生物标志物.

科学领域:

肝病学肝病学是一种肝病学.
免疫学免疫学免疫学
微生物组研究微生物组研究

背景情况:

主要胆道胆炎 (PBC) 是一种慢性自身免疫性肝病,影响胆道,主要发生在中年妇女身上.
抗线粒体抗体 (AMA) 是PBC的一个标志,向线粒体的2oxo-酸脱酶复合体.
Ursodeoxycholic 酸 (UDCA) 是标准疗法,但患者对治疗的反应有所不同.

研究的目的:

审查有关肠道微生物群组成变化的现有研究,在PBC患者.
探索肠道微生物群作为UDCA治疗疗效的生物标志物的潜力.
了解肠道微生物群在PBC病原和治疗中的作用.

主要方法:

对分析肠道微生物群组成的研究进行文献综述.
在PBC患者的UDCA治疗前后微生物特征的比较.
检查可能将肠道微生物群与PBC联系的生化途径.

主要成果:

目前,关于在PBC中UDCA治疗后肠道微生物群变化的研究有限.
需要进一步的研究来澄清涉及的特定生化途径.
肠道微生物群作为UDCA反应的预测生物标志物的作用需要更多的研究.

结论:

在PBC患者的UDCA治疗期间肠道微生物群组成的变化需要进一步调查.
了解这些微生物转变可能会导致新的治疗策略和生物标志物.
肠道微生物群,UDCA和PBC病原体之间的相互作用仍然是未来重大研究的领域.

更多相关视频

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

相关概念视频

Chronic Bowel Disorders: Introduction

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

What is Monogastric Digestion?

What is Monogastric Digestion?

The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...